BioSpace News Archive

Zymeworks Inc. announced 11 presentations including new data from its clinical and preclinical development-stage programs at the 2023 American Association for Cancer Research Annual Meeting being held in Orlando, Florida.

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”) today announced an exclusive worldwide agreement with NE Scientific, LLC, a leader in biophysics simulation, to develop a GPU-accelerated software solution for modeling of drug infusions delivered with the ClearPoint SmartFlow® cannula.

TELA Bio, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.

GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, announced it will release financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023.

PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2023 financial results on Tuesday, May 2, 2023, at 4:30 pm Eastern Time.

Calyxt, Inc., a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission by Calyxt on February 14, 2023, and amended on April 14, 2023, has been declared effective by the SEC.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010 dosing has been formally reviewed in both of the current Phase 1 clinical trials, and the Company is now enrolling the final dose cohort in the cancer trial.

GENFIT announced the filing of its 2022 Universal Registration Document with the Autorité des marchés financiers and its Annual Report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) announced today that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate as a panel presenter at the Canaccord Genuity Horizons in Oncology Virtual Conference.

Pulmonx Corporation, a global leader in minimally invasive treatments for lung disease, announced that it will release financial results for the first quarter of 2023 after the close of trading on Tuesday, May 2, 2023.